Table 2. Meta-analysis of ADRs in LN patients under leflunomide and cyclophosphamide therapy.

ADRs	Included studies	Trials n/N	Control n/N	RR (95% CI)	P value	Heterogeneity
ALT abnormity	9	16/225	32/222	0.53(0.33, 0.87)**	0.01	P = 0.58, I2 = 0%
Gastrointesntial Reaction	8	19/198	33/204	0.73(0.45, 1.17)	0.19	P = 0.50, I2 = 0%
Rash	7	9/176	6/171	1.32(0.54, 3.23)	0.55	P = 0.70, I2 = 0%
Alopecia	7	6/167	21/173	0.38(0.17, 0.85)*	0.02	P = 0.99, I2 = 0%
Leukopenia	6	1/134	11/129	0.25(0.08, 0.77)*	0.02	P = 1.00, I2 = 0%
Infection	5	11/121	23/121	0.54(0.32, 0.92)*	0.02	P = 0.31, I2 = 0%
Menoxenia	4	0/106	6/106	0.25(0.05, 1.15)	0.07	P = 0.99, I2 = 0%
Herpes zoster	2	0/65	2/65	0.33(0.04, 3.12)	0.34	P = 1.00, I2 = 0%
Total	7	32/187	69/182	0.45(0.31–0.64)**	<0.001	P = 0.91, I2 = 0%

Note: n/N, total events / patients of the group

*P≤0.05

**P≤0.01.